GB2272375A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB2272375A
GB2272375A GB9325480A GB9325480A GB2272375A GB 2272375 A GB2272375 A GB 2272375A GB 9325480 A GB9325480 A GB 9325480A GB 9325480 A GB9325480 A GB 9325480A GB 2272375 A GB2272375 A GB 2272375A
Authority
GB
United Kingdom
Prior art keywords
iron
pharmaceutically acceptable
acceptable salt
alginic acid
metallic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9325480A
Other versions
GB2272375B (en
GB9325480D0 (en
Inventor
Tatyana Nikolaevna Sentsova
Viktor Semenovich Yakubovich
Ljudmila Pavlovna Raskina
Valery Alexandrovich Barabanov
Anatoly Afanasievich Ilchenko
Vladimir Grigorie Zhukhovitsky
Yanis Martynovich Mikelson
Anatoly Sergeevich Loginov
Nadezhda Timofeevn Melnichenko
Dzintra Alfredovna Leinasare
Leonid Iosifovich Aruin
Irina Anatol Smotrova
Lev Kosntantinovich Sokolov
Viktor Vladimirovic Kondrashov
Tamara Mikhailovna Titova
Valeria Efimovna Selezneva
Vladimir Alexandrovich Makarov
Valery Vladimirovic Elmanovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VNII MED POLIMEROV
Original Assignee
VNII MED POLIMEROV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VNII MED POLIMEROV filed Critical VNII MED POLIMEROV
Publication of GB9325480D0 publication Critical patent/GB9325480D0/en
Publication of GB2272375A publication Critical patent/GB2272375A/en
Application granted granted Critical
Publication of GB2272375B publication Critical patent/GB2272375B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition comprises alginic acid and/or its pharmaceutically acceptable salt and a metallic compound chosen from a group consisting of iron-ammonium alum, iron glycerophosphate, iron lactate, reduced iron, base bismuth nitrate, potassium alum, aluminium hydroxide, kaoline, barium sulphate, calcium gluconate, calcium chloride, calcium carbonate or their mixture, at the following ratio of the components in per cent by weight: alginic acid and/or its pharmaceutically acceptable salt 5-91, metallic compound the balance. The composition will find use for prophylaxis and treatment of gastro-intestinal disturbances, flesh wounds and as a hemostatic agent.
GB9325480A 1992-04-10 1992-04-10 Pharmaceutical composition Expired - Fee Related GB2272375B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU1992/000074 WO1993020826A1 (en) 1992-04-10 1992-04-10 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
GB9325480D0 GB9325480D0 (en) 1994-03-09
GB2272375A true GB2272375A (en) 1994-05-18
GB2272375B GB2272375B (en) 1996-02-14

Family

ID=20129712

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9325480A Expired - Fee Related GB2272375B (en) 1992-04-10 1992-04-10 Pharmaceutical composition

Country Status (5)

Country Link
JP (1) JPH06508641A (en)
DE (1) DE4294862T1 (en)
GB (1) GB2272375B (en)
NL (1) NL9220019A (en)
WO (1) WO1993020826A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036599A1 (en) * 1996-03-29 1997-10-09 Marcin Krotkiewski Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1269826B (en) * 1994-05-24 1997-04-15 Paolo Minoia USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS
JP3114016B2 (en) * 1998-05-15 2000-12-04 株式会社ホギメディカル Wound hemostatic material having cell adhesion promoting effect
GB9812278D0 (en) * 1998-06-09 1998-08-05 Bristol Myers Squibb Co Use of a wound dressing in the treatment of acute wounds
AU2003252694A1 (en) * 2002-07-26 2004-02-16 Mikasa Seiyaku Co., Ltd. External preparation
CA2499014A1 (en) * 2002-09-16 2004-03-25 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
PL2137191T3 (en) 2007-03-29 2016-12-30 Peripheral opioid receptor antagonists and uses thereof
PT2139890E (en) 2007-03-29 2014-09-03 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391799A (en) * 1980-02-15 1983-07-05 The United States Of America As Represented By The Secretary Of The Army Protective gel composition for treating white phosphorus burn wounds
EP0206626A2 (en) * 1985-06-13 1986-12-30 Barry James Dr. Marshall Use of Bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by Campylobacter polyridis
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391799A (en) * 1980-02-15 1983-07-05 The United States Of America As Represented By The Secretary Of The Army Protective gel composition for treating white phosphorus burn wounds
EP0206626A2 (en) * 1985-06-13 1986-12-30 Barry James Dr. Marshall Use of Bismuth for the manufacture of a medicament for the treatment of gastrointestinal disorders induced by Campylobacter polyridis
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036599A1 (en) * 1996-03-29 1997-10-09 Marcin Krotkiewski Pharmaceutical preparation for the treatment of gastritis, reflux oesophagitis, duodenitis, dyspepsia and ulcer disease

Also Published As

Publication number Publication date
DE4294862T1 (en) 1994-06-09
JPH06508641A (en) 1994-09-29
NL9220019A (en) 1994-04-05
WO1993020826A1 (en) 1993-10-28
GB2272375B (en) 1996-02-14
GB9325480D0 (en) 1994-03-09

Similar Documents

Publication Publication Date Title
GB2272375A (en) Pharmaceutical composition
CA2332038A1 (en) Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
MY109928A (en) Fatty acid treatment
KR100261669B1 (en) Substituted pyrazolylbenzene sulfonamides for the treatment of inflammation
CA2208078A1 (en) Formulations and methods for reducing skin irritation
GB1520197A (en) Stable antibiotic compositions
AR004701A1 (en) 2-AZETIDINONES SUBSTITUTED WITH SUGARS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH COMPOSITION, USE OF SUCH COMPOUNDS TO MANUFACTURE MEDICINES AND EQUIPMENT.
MY109531A (en) Effervescent antacid
RS97703A (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparation containing said compounds
HUT72749A (en) Substituted 1-oxo-1,2-dihydro-isoguino-linoyl- and 1,1-dioxo-2h-1,2-benzothiazinoyl-guanidines, process for producing them, use of them in therapy and pharmaceutical compositions containing them
CA2132416A1 (en) Use of transglutaminase inhibitor for the treatment of scar tissue
CA2148194A1 (en) Cyclopeptides of the formula i
IL111036A (en) Beta-alanine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
AU4603293A (en) Antiperspirant actives and compositions
CA2298645A1 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
ATE132328T1 (en) COMPOSITIONS FOR BEVERAGES CONTAINING PSYLLIUM
PL318146A1 (en) Two- and three-component fungicidal mixtures
RU97102146A (en) TWO AND THREE COMPONENT FUNGICIDAL MIXTURES
DE02748548T1 (en) CALCIUM-L-THREONATE FOR PREVENTING OR TREATING BONE FRACTURES
CA2211177A1 (en) Agent for acting upon bone formation disturbances containing alkaline citrates, lactates and/or malates
CA2067374A1 (en) Osteogenesis promoter
WO1990001321A3 (en) Method for treating and preventing loss of bone mass
IT1260151B (en) Pharmaceutical composition useful for the treatment of gastroenteric diseases, wounds and burns and as a haemostatic agent
IL112110A0 (en) Octahydro-1h-isoindoles and pharmaceutical compositions containing them
DE3362246D1 (en) Magnesium salt of chenodeoxycholic acid and ursodeoxycholic acid, the process for its preparation, and therapeutic compositions which contain it as active principle

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19980410